The Medicines and Healthcare products Regulatory Agency (MHRA) has started consultation on Nuromol to make the drug available without the need to visit a community pharmacy.
The consultation will remain open to public until June 3 for their response to a potential reclassification of Nuromol to a general sale list medicine. The drug contains ibuprofen and paracetamol and could become available in a pack of six tablets, if it is reclassified.
At present the drug is only available for purchase in pharmacies, under the supervision of a pharmacist.
Nuromol is used for the temporary relief of mild to moderate pain associated with migraine, headache, backache, period pain, dental pain, rheumatic and muscular pain, pain of non-serious arthritis, cold and flu symptoms, sore throat, and fever when paracetamol or ibuprofen alone have not provided adequate pain relief.
While most people can take paracetamol, ibuprofen isn’t suitable for everyone and it is important that people do not exceed the recommended dose or take more than one paracetamol product at once.
“We would like to hear from anyone who may be affected by this proposed change in classification,” the medicines regulator said.
Dr Sarah Branch, a director at the MHRA, said:” Every response received will help us gain a better picture of whether people think Nuromol can be made available safely without the need to visit a pharmacy.
“We want to hear from as many people as possible, and therefore we urge people to respond to our consultation and let us know their views.”
